Pharma Marketing: Pretty Much the Same As Every Other Kind of Marketing

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


Charles Ornstein and Ryann Grochowski Jones published a story yesterday that’s gotten a lot of attention. It’s an examination of where pharmaceutical companies spend most of their marketing budgets:

The drugs most aggressively promoted to doctors typically aren’t cures or even big medical breakthroughs. Some are top sellers, but most are not. Instead, they are newer drugs that manufacturers hope will gain a foothold, sometimes after failing to meet Wall Street’s early expectations.

“They may have some unique niche in the market, but they are fairly redundant with other therapies that are already available,” said Dr. Joseph Ross, an associate professor of medicine and public health at Yale University School of Medicine. “Many of these, you could call me-too drugs.”

Maybe this is just my marketing background blinding me to an obvious outrage, but….what else would you expect? This is what every company does. If you’re in marketing, you spend a lot of money on new product launches and you spend a lot of money where you most need to differentiate yourself. This is nothing unique to pharma. It’s just the common-sense way that marketing works.

There’s a lot that’s wrong with pharmaceutical R&D priorities, and there’s also a lot that’s wrong with pharmaceutical marketing strategies. But spending a lot of money on new products that have entrenched competitors? If that’s wrong, then every consumer products company on the planet is doing something wrong. I’m a bit at a loss to figure out what the story is supposed to be here.

We've never been very good at being conservative.

And usually, that serves us well in doing the ambitious, hard-hitting journalism that you turn to Mother Jones for. But it also means we can't afford to come up short when it comes to scratching together the funds it takes to keep our team firing on all cylinders, and the truth is, we finished our budgeting cycle on June 30 about $100,000 short of our online goal.

This is no time to come up short. It's time to fight like hell, as our namesake would tell us to do, for a democracy where minority rule cannot impose an extreme agenda, where facts matter, and where accountability has a chance at the polls and in the press. If you value our reporting and you can right now, please help us dig out of the $100,000 hole we're starting our new budgeting cycle in with an always-needed and always-appreciated donation today.

payment methods

We've never been very good at being conservative.

And usually, that serves us well in doing the ambitious, hard-hitting journalism that you turn to Mother Jones for. But it also means we can't afford to come up short when it comes to scratching together the funds it takes to keep our team firing on all cylinders, and the truth is, we finished our budgeting cycle on June 30 about $100,000 short of our online goal.

This is no time to come up short. It's time to fight like hell, as our namesake would tell us to do, for a democracy where minority rule cannot impose an extreme agenda, where facts matter, and where accountability has a chance at the polls and in the press. If you value our reporting and you can right now, please help us dig out of the $100,000 hole we're starting our new budgeting cycle in with an always-needed and always-appreciated donation today.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate